DERA

Across TCGA pan-cancer cohorts, DERA mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DERA data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DERA mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated DERA expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where DERA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.628	0.419	.005	37	view →
CCRCC	OS	Quartile	II,III,IV	0.806	0.449	.022	13	view →
HNSC	OS	Tertile	II,III,IV	0.642	0.837	.011	7	view →
LSCC	DFS	Tertile	All	1.000	0.468	.008	6	view →
LUAD	OS	Median	All	0.919	0.997	.007	4	view →
GBM	DFS	Quartile	All	0.693	0.888	.015	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DERA–PDAC (OS)

Open the PDAC breakdown →